Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.68 Billion
CN¥19.64 Billion CNY
Market Cap Rank
#4496 Global
#466 in China
Share Price
CN¥12.28
Change (1 day)
+1.82%
52-Week Range
CN¥9.89 - CN¥14.48
All Time High
CN¥93.63
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meni… Read more

Walvax BioTech (300142) - Net Assets

Latest net assets as of September 2025: CN¥10.94 Billion CNY

Based on the latest financial reports, Walvax BioTech (300142) has net assets worth CN¥10.94 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥13.25 Billion) and total liabilities (CN¥2.31 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥10.94 Billion
% of Total Assets 82.58%
Annual Growth Rate 46.39%
5-Year Change 46.64%
10-Year Change 280.58%
Growth Volatility 327.13

Walvax BioTech - Net Assets Trend (2007–2024)

This chart illustrates how Walvax BioTech's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Walvax BioTech (2007–2024)

The table below shows the annual net assets of Walvax BioTech from 2007 to 2024.

Year Net Assets Change
2024-12-31 CN¥11.51 Billion +0.99%
2023-12-31 CN¥11.40 Billion +3.69%
2022-12-31 CN¥10.99 Billion +9.91%
2021-12-31 CN¥10.00 Billion +27.41%
2020-12-31 CN¥7.85 Billion +38.51%
2019-12-31 CN¥5.67 Billion +7.80%
2018-12-31 CN¥5.26 Billion +47.74%
2017-12-31 CN¥3.56 Billion +0.96%
2016-12-31 CN¥3.52 Billion +16.53%
2015-12-31 CN¥3.02 Billion -5.86%
2014-12-31 CN¥3.21 Billion +9.31%
2013-12-31 CN¥2.94 Billion -7.29%
2012-12-31 CN¥3.17 Billion +16.81%
2011-12-31 CN¥2.71 Billion +6.37%
2010-12-31 CN¥2.55 Billion +1360.26%
2009-12-31 CN¥174.69 Million +77.61%
2008-12-31 CN¥98.36 Million +457.06%
2007-12-31 CN¥17.66 Million --

Equity Component Analysis

This analysis shows how different components contribute to Walvax BioTech's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 47255.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥3.03 Billion 32.12%
Common Stock CN¥1.60 Billion 16.96%
Other Components CN¥4.80 Billion 50.92%
Total Equity CN¥9.43 Billion 100.00%

Walvax BioTech Competitors by Market Cap

The table below lists competitors of Walvax BioTech ranked by their market capitalization.

Company Market Cap
SBI Cards and Payment Services Limited
NSE:SBICARD
 		$2.40 Billion
Vishal Mega Mart Ord Shs
NSE:VMM
 		$2.40 Billion
LG Display
KO:034220
 		$2.40 Billion
Inventrust Properties Corp
NYSE:IVT
 		$2.40 Billion
China State Construction International Holdings Limited
PINK:CCOHF
 		$2.39 Billion
USA Rare Earth, Inc.
NASDAQ:USAR
 		$2.39 Billion
SEACOAST BKG FLA DL-10
F:SBG1
 		$2.39 Billion
Allreal
PINK:ALRHF
 		$2.39 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Walvax BioTech's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 9,349,276,209 to 9,429,543,133, a change of 80,266,924 (0.9%).
  • Net income of 142,160,415 contributed positively to equity growth.
  • Dividend payments of 40,940,003 reduced retained earnings.
  • Other comprehensive income decreased equity by 776,486,473.
  • Other factors increased equity by 755,532,985.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥142.16 Million +1.51%
Dividends Paid CN¥40.94 Million -0.43%
Other Comprehensive Income CN¥-776.49 Million -8.23%
Other Changes CN¥755.53 Million +8.01%
Total Change CN¥- 0.86%

Book Value vs Market Value Analysis

This analysis compares Walvax BioTech's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.08x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 65.31x to 2.08x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2007-12-31 CN¥0.19 CN¥12.28 x
2008-12-31 CN¥0.16 CN¥12.28 x
2009-12-31 CN¥0.17 CN¥12.28 x
2010-12-31 CN¥2.09 CN¥12.28 x
2011-12-31 CN¥1.93 CN¥12.28 x
2012-12-31 CN¥2.10 CN¥12.28 x
2013-12-31 CN¥1.91 CN¥12.28 x
2014-12-31 CN¥2.01 CN¥12.28 x
2015-12-31 CN¥1.63 CN¥12.28 x
2016-12-31 CN¥2.28 CN¥12.28 x
2017-12-31 CN¥1.97 CN¥12.28 x
2018-12-31 CN¥2.98 CN¥12.28 x
2019-12-31 CN¥3.16 CN¥12.28 x
2020-12-31 CN¥4.23 CN¥12.28 x
2021-12-31 CN¥5.30 CN¥12.28 x
2022-12-31 CN¥5.66 CN¥12.28 x
2023-12-31 CN¥5.84 CN¥12.28 x
2024-12-31 CN¥5.90 CN¥12.28 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Walvax BioTech utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 1.51%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.04%
  • • Asset Turnover: 0.19x
  • • Equity Multiplier: 1.56x
  • Recent ROE (1.51%) is below the historical average (8.73%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2007 42.05% 5.83% 0.59x 12.32x CN¥5.66 Million
2008 35.28% 18.85% 0.61x 3.07x CN¥24.86 Million
2009 43.70% 31.92% 0.62x 2.21x CN¥58.86 Million
2010 6.05% 43.04% 0.12x 1.17x CN¥-100.67 Million
2011 7.65% 43.80% 0.16x 1.11x CN¥-63.81 Million
2012 7.88% 43.31% 0.12x 1.51x CN¥-62.61 Million
2013 1.75% 8.21% 0.10x 2.24x CN¥-226.36 Million
2014 4.98% 19.95% 0.12x 2.07x CN¥-144.87 Million
2015 -36.81% -83.59% 0.16x 2.74x CN¥-1.07 Billion
2016 2.20% 11.92% 0.09x 1.97x CN¥-250.27 Million
2017 -17.74% -80.38% 0.11x 1.94x CN¥-839.87 Million
2018 22.87% 119.66% 0.12x 1.58x CN¥588.80 Million
2019 2.92% 12.66% 0.16x 1.44x CN¥-344.54 Million
2020 15.33% 34.13% 0.30x 1.47x CN¥348.71 Million
2021 5.04% 12.35% 0.25x 1.61x CN¥-420.68 Million
2022 8.02% 14.33% 0.33x 1.69x CN¥-179.73 Million
2023 4.49% 10.19% 0.26x 1.67x CN¥-515.54 Million
2024 1.51% 5.04% 0.19x 1.56x CN¥-800.79 Million

Industry Comparison

This section compares Walvax BioTech's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Walvax BioTech (300142) CN¥10.94 Billion 42.05% 0.21x $2.39 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million